Intech made co-development alliance with Twi to enter niche inhaler market of US.
Intech got the permission of clinical trials for its asthma product Duasma in China.
Intech got the preliminary approval and will submit the application of final approval for listing on OTC stock market soon.
Intech has submitted its application for IPO, and triggered its multinational clinical trials and international business development.
Intech new plant accelerates the pace and expands the capacity to fulfill the international market demand.
Intech signed the license and supply agreement with China Resources Saike Pharmaceutical, both companies will form an alliance and seize the niche market.
Intech iLEF MDI platform is praised widely and will move quickly in China market.
Intech got the qualification report of sample testing for Duasma, an inhaler product treating Asthma, and accelerate the market expansion in Taiwan and China.
Intech got the license of Duasma, an inhaler product treating Asthma, in Hong Kong and accelerate the market expansion in the area of Greater China.
Intech has launched a reliever drug of asthma Synvent in Taiwan and targets the 2.6 billion global market in the future.
/ Pages： 2 Total items：19
Board of Directors
益得生技股份有限公司 版權所有 請勿任意轉載 隱私權政策
114台北市內湖區瑞光路358巷36號3樓 電話：(02)7721-8877 傳真：(02)7721-8800
Intech Biopharm Corporation © 2014 All Rights Reserved.
3F., No.36, Ln.358, Ruiguang Rd., Neihu Dist., Taipei City 114, Taiwan, R.O.C. Tel：+886-02-7721-8877 Fax：+886-02-7721-8800